Limosilactobacillus reuteri AMBV339

Limosilactobacillus reuteri AMBV339 (probiotic strain) · DSM-Firmenich Switzerland AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Limosilactobacillus reuteri AMBV339, covering 2025-05-09 to 2025-05-09. Get the full timeline:

Most recent: Clinical Trial Update: Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health of Healthy Adult Women (The VIAB2L Project) [NA]

See pricing